CG Oncology bladder cancer therapy cuts recurrence risk by 68% in Phase 3 trial
CG Oncology, Inc. reported positive topline results from PIVOT-006, its Phase 3 registrational trial of cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC) following complete tumor resection. The company said the therapy reduced the risk of tumor recurrence by 68% versus the control arm, with a hazard ratio of 0.32 over a median 17 months of follow-up as of October 26, 2026.


